Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 24330229)

1.

Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.

Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J.

Pain Med. 2013 Dec;14(12):1954-63. doi: 10.1111/pme.12276. Epub 2013 Oct 30.

PMID:
24330229
2.

A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

BMC Neurol. 2011 Jan 20;11:7. doi: 10.1186/1471-2377-11-7.

3.

Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.

Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.

Pain Pract. 2012 Jun;12(5):382-93. doi: 10.1111/j.1533-2500.2011.00515.x. Epub 2011 Oct 18.

PMID:
22004531
4.

Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.

Saldaña MT, Pérez C, Navarro A, Masramón X, Rejas J.

Clin Drug Investig. 2012 Jun 1;32(6):401-12. doi: 10.2165/11599400-000000000-00000.

PMID:
22480279
5.
6.

A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.

Pain Med. 2012 May;13(5):699-710. doi: 10.1111/j.1526-4637.2012.01375.x.

PMID:
22594706
7.

Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

Pain Med. 2010 May;11(5):719-31. doi: 10.1111/j.1526-4637.2010.00824.x. Epub 2010 Mar 22.

PMID:
20345618
8.

A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings.

Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J.

Pain Pract. 2010 Jan-Feb;10(1):31-41. doi: 10.1111/j.1533-2500.2009.00312.x.

PMID:
20629966
9.

A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.

Morera-Domínguez C, Ceberio-Balda F, Flórez-García M, Masramón X, López-Gómez V.

Clin Drug Investig. 2010;30(8):517-31. doi: 10.2165/11536280-000000000-00000.

PMID:
20513162
10.

Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Blanco Tarrio E, Gálvez Mateos R, Zamorano Bayarri E, López Gómez V, Pérez Páramo M.

Clin Drug Investig. 2013 Sep;33(9):633-45. doi: 10.1007/s40261-013-0116-7. Erratum in: Clin Drug Investig. 2014 May;34(5):371.

11.
12.

Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.

Pérez C, Navarro A, Saldaña MT, Figueras-Balsells M, Muñoz-Tudurí M, Rejas J.

Clin J Pain. 2013 Jun;29(6):471-7. doi: 10.1097/AJP.0b013e3182652c2b.

PMID:
23328322
13.

Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.

Flórez-García M, Ceberio-Balda F, Morera-Domínguez C, Masramón X, Pérez M.

Pain Pract. 2011 Jul-Aug;11(4):369-80. doi: 10.1111/j.1533-2500.2010.00430.x. Epub 2010 Dec 29.

PMID:
21199310
14.

A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.

Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z.

J Med Econ. 2012;15(2):207-18. doi: 10.3111/13696998.2011.632797. Epub 2011 Nov 17.

PMID:
22017236
15.

Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the U.K.

Berger A, Sadosky A, Dukes E, Edelsberg J, Oster G.

Pain Pract. 2009 Jan-Feb;9(1):18-34. doi: 10.1111/j.1533-2500.2008.00226.x. Epub 2008 Oct 30.

PMID:
19019054
16.

A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.

Prettyjohns M, Sandelin R, Lister S, Norrefalk JR.

J Med Econ. 2012;15(6):1097-109. doi: 10.3111/13696998.2012.704458. Epub 2012 Jul 5.

PMID:
22712872
17.

An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.

Prim Care Diabetes. 2012 Dec;6(4):303-12. doi: 10.1016/j.pcd.2012.03.001. Epub 2012 May 15.

PMID:
22595032
18.
19.

Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.

Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J.

Rheumatol Int. 2010 Jun;30(8):1005-15. doi: 10.1007/s00296-009-1086-1. Epub 2009 Oct 2.

20.

Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.

Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.

J Med Econ. 2013;16(5):596-605. doi: 10.3111/13696998.2013.773333. Epub 2013 Mar 4.

PMID:
23409950
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk